A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

BACKGROUND: Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). METHODS: Meta-analysis of randomized controlled trials (RCTs) evaluating fulvestrant 500 mg in postme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer
Main Authors: Robertson, John F. R., Jiang, Zefei, Di Leo, Angelo, Ohno, Shinji, Pritchard, Kathleen I., Ellis, Matthew, Bradbury, Ian, Campbell, Christine
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821663/
https://ncbi.nlm.nih.gov/pubmed/31079343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-019-00973-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados